Ieq Capital, LLC Nektar Therapeutics Transaction History

Ieq Capital, LLC

$8.04 Billion
Q3 2024

A detailed history of Ieq Capital, LLC transactions in Nektar Therapeutics stock. As of the latest transaction made, Ieq Capital, LLC holds 21,978 shares of NKTR stock, worth $20,439. This represents 0.0% of its overall portfolio holdings.

Number of Shares

21,978

Previous 21,978 -0.0%

Holding current value

$20,439

Previous $27,000 3.7%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$0.9 - $1.83 $1,949 - $3,963	-2,166 Reduced 8.97%	21,978 $27,000
Q1 2024 May 08, 2024	BUY	$0.49 - $0.96 $5,169 - $10,128	10,550 Added 77.61%	24,144 $22,000
Q4 2023 Feb 07, 2024	BUY	$0.42 - $0.57 $840 - $1,140	2,000 Added 17.25%	13,594 $7,000
Q4 2022 Feb 03, 2023	SELL	$2.03 - $4.28 $115,291 - $243,078	-56,794 Reduced 83.05%	11,594 $26,000
Q3 2022 Nov 03, 2022	SELL	$3.04 - $5.14 $13,680 - $23,130	-4,500 Reduced 6.17%	68,388 $219,000
Q2 2022 Jul 27, 2022	SELL	$3.17 - $6.17 $1,245 - $2,424	-393 Reduced 0.54%	72,888 $277,000
Q1 2022 Apr 26, 2022	BUY	$4.16 - $13.72 $940 - $3,100	226 Added 0.31%	73,281 $395,000
Q4 2021 Jan 31, 2022	BUY	$10.83 - $18.41 $613,985 - $1.04 Million	56,693 Added 346.49%	73,055 $987,000
Q3 2021 Nov 09, 2021	BUY	$13.07 - $18.84 $213,851 - $308,260	16,362 New	16,362 $294,000
Q1 2021 May 04, 2021	SELL	$16.56 - $25.46 $4.41 Million - $6.79 Million	-266,559 Closed	0 $0
Q4 2020 Feb 03, 2021	BUY	$15.77 - $19.03 $4.2 Million - $5.07 Million	266,559 New	266,559 $4.53 Million

Others Institutions Holding NKTR

# of Institutions

145

Shares Held

139M

Call Options Held

32.6K

Put Options Held

14.1K

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ieq Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ieq Capital, LLC with notifications on news.

Account